296 related articles for article (PubMed ID: 32606601)
1. In vitro and in vivo Anti-Tumor Effects of Pan-HER Inhibitor Varlitinib on Cholangiocarcinoma Cell Lines.
Dokduang H; Jamnongkarn W; Promraksa B; Suksawat M; Padthaisong S; Thanee M; Phetcharaburanin J; Namwat N; Sangkhamanon S; Titapun A; Khuntikeo N; Klanrit P; Loilome W
Drug Des Devel Ther; 2020; 14():2319-2334. PubMed ID: 32606601
[TBL] [Abstract][Full Text] [Related]
2. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
[TBL] [Abstract][Full Text] [Related]
3. The Effect of the EGFR - Targeting Compound 3-[(4-Phenylpyrimidin-2-yl) Amino] Benzene-1-Sulfonamide (13f) against Cholangiocarcinoma Cell Lines.
Samatiwat P; Tabtimmai L; Suphakun P; Jiwacharoenchai N; Toviwek B; Kukongviriyapan V; Gleeson MP; Choowongkomon K
Asian Pac J Cancer Prev; 2021 Feb; 22(2):381-390. PubMed ID: 33639651
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Tumor Growth against Chemoresistant Cholangiocarcinoma by a Proapoptotic Peptide Targeting Interleukin-4 Receptor.
Permpoon U; Khan F; Vadevoo SMP; Gurung S; Gunassekaran GR; Kim MJ; Kim SH; Thuwajit P; Lee B
Mol Pharm; 2020 Nov; 17(11):4077-4088. PubMed ID: 32881535
[TBL] [Abstract][Full Text] [Related]
5. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of celastrol by inhibition of proliferation, invasion, and migration in cholangiocarcinoma via PTEN/PI3K/Akt pathway.
Zhu B; Wei Y
Cancer Med; 2020 Jan; 9(2):783-796. PubMed ID: 31957323
[TBL] [Abstract][Full Text] [Related]
7. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
Zhang Z; Oyesanya RA; Campbell DJ; Almenara JA; Dewitt JL; Sirica AE
Hepatology; 2010 Sep; 52(3):975-86. PubMed ID: 20607690
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
9. Effect of β-Eudesmol on NQO1 suppression-enhanced sensitivity of cholangiocarcinoma cells to chemotherapeutic agents.
Srijiwangsa P; Ponnikorn S; Na-Bangchang K
BMC Pharmacol Toxicol; 2018 Jun; 19(1):32. PubMed ID: 29914576
[TBL] [Abstract][Full Text] [Related]
10. Actinidia arguta (Hardy Kiwi) Root Extract Exerts Anti-cancer Effects via Mcl-1-Mediated Apoptosis in Cholangiocarcinoma.
Zhao X; Wen F; Wang W; Lu Z; Guo Q
Nutr Cancer; 2019; 71(2):246-256. PubMed ID: 30633583
[TBL] [Abstract][Full Text] [Related]
11. Antitumor Efficacy of the Herbal Recipe Benja Amarit against Highly Invasive Cholangiocarcinoma by Inducing Apoptosis both In Vitro and In Vivo.
Yapasert R; Lertprasertsuk N; Subhawa S; Poofery J; Sripanidkulchai B; Banjerdpongchai R
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32784671
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
Chen MH; Chiang KC; Cheng CT; Huang SC; Chen YY; Chen TW; Yeh TS; Jan YY; Wang HM; Weng JJ; Chang PM; Liu CY; Li CP; Chao Y; Chen MH; Huang CY; Yeh CN
Oncotarget; 2014 May; 5(9):2372-89. PubMed ID: 24796583
[TBL] [Abstract][Full Text] [Related]
13. Simvastatin and atorvastatin as inhibitors of proliferation and inducers of apoptosis in human cholangiocarcinoma cells.
Buranrat B; Senggunprai L; Prawan A; Kukongviriyapan V
Life Sci; 2016 May; 153():41-9. PubMed ID: 27098189
[TBL] [Abstract][Full Text] [Related]
14. Artesunate and chloroquine induce cytotoxic activity on cholangiocarcinoma cells via different cell death mechanisms.
Guragain D; Seubwai W; Kobayashi D; Silsinivanit A; Vaeteewoottacharn K; Sawanyawisuth K; Wongkham C; Wongkham S; Araki N; Cha'on U
Cell Mol Biol (Noisy-le-grand); 2018 Jul; 64(10):113-118. PubMed ID: 30084802
[TBL] [Abstract][Full Text] [Related]
15. Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma.
Vaeteewoottacharn K; Kariya R; Matsuda K; Taura M; Wongkham C; Wongkham S; Okada S
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1551-62. PubMed ID: 23877657
[TBL] [Abstract][Full Text] [Related]
16. Anti-Proliferative Effects of Compound A and Its Effect in Combination with Cisplatin in Cholangiocarcinoma Cells.
Junking M; Rattanaburee T; Panya A; Budunova I; Haegeman G; Yenchitsomanus PT
Asian Pac J Cancer Prev; 2020 Sep; 21(9):2673-2681. PubMed ID: 32986368
[TBL] [Abstract][Full Text] [Related]
17. A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression.
Liang S; Guo H; Ma K; Li X; Wu D; Wang Y; Wang W; Zhang S; Cui Y; Liu Y; Sun L; Zhang B; Xin M; Zhang N; Zhou H; Liu Y; Wang J; Liu L
Cancer Res; 2021 Dec; 81(23):5889-5903. PubMed ID: 34580062
[TBL] [Abstract][Full Text] [Related]
18. Luteolin arrests cell cycling, induces apoptosis and inhibits the JAK/STAT3 pathway in human cholangiocarcinoma cells.
Aneknan P; Kukongviriyapan V; Prawan A; Kongpetch S; Sripa B; Senggunprai L
Asian Pac J Cancer Prev; 2014; 15(12):5071-6. PubMed ID: 24998588
[TBL] [Abstract][Full Text] [Related]
19. Targeted Modulation of FAK/PI3K/PDK1/AKT and FAK/p53 Pathways by Cucurbitacin B for the Antiproliferation Effect Against Human Cholangiocarcinoma Cells.
Klungsaeng S; Kukongviriyapan V; Prawan A; Kongpetch S; Senggunprai L
Am J Chin Med; 2020; 48(6):1475-1489. PubMed ID: 32907364
[TBL] [Abstract][Full Text] [Related]
20. Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells.
Kitagawa K; Moriya K; Kaji K; Saikawa S; Sato S; Nishimura N; Namisaki T; Akahane T; Mitoro A; Yoshiji H
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]